Patents Assigned to ZymoGenetics
  • Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
    Patent number: 7749965
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: July 6, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • IL-21 production in prokaryotic hosts
    Patent number: 7745176
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: June 29, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Douglas C. Covert
  • Murine zcytor17 ligand polypeptides
    Patent number: 7740834
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: June 22, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E Kuestner
  • Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
    Patent number: 7727518
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: June 1, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20100129384
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: November 5, 2009
    Publication date: May 27, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20100130728
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 27, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: MARK W. RIXON, JANE A. GROSS
  • Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
    Patent number: 7723048
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 25, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine Bilsborough, Jane A. Gross
  • Method of treating fibroproliferative disorders
    Patent number: 7722870
    Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: May 25, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Cytokine receptor
    Patent number: 7723298
    Abstract: Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: May 25, 2010
    Assignee: ZymoGenetics, Inc.
    Inventor: Wenfeng Xu
  • Anti-IL-TIF antibodies and methods of using in inflammation
    Patent number: 7718172
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: May 18, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20100111948
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Application
    Filed: October 16, 2009
    Publication date: May 6, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
  • ANTI-IL-20, ANTI-IL-22 AND ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20100111960
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 6, 2010
    Applicant: ZymoGenetics, Inc.
    Inventor: Wenfeng Xu
  • SOLUBLE IL-17RCX4 AND METHODS OF USING IN INFLAMMATION
    Publication number: 20100113748
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
    Type: Application
    Filed: October 15, 2009
    Publication date: May 6, 2010
    Applicant: Zymogenetics, Inc.
    Inventors: Rolf E. Kuestner, Zeren Gao, Steven D. Levin, Mark W. Rixon
  • Methods of using soluble heterodimeric cytokine receptor
    Patent number: 7704950
    Abstract: A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: April 27, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Julia E. Novak, Donald C. Foster, Wenfeng Xu, Stephen R. Jaspers
  • HUMAN CYTOKINE RECEPTOR
    Publication number: 20100099850
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 22, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • INTERLEUKIN-17 RECEPTOR HOMOLOGUE
    Publication number: 20100099849
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
    Type: Application
    Filed: September 23, 2009
    Publication date: April 22, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: Scott R. Presnell, Steven K. Burkhard, Sarah L. Pownder
  • Growth factor homolog zvegf3
    Patent number: 7691981
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: April 6, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
  • Human zven polynucleotides
    Patent number: 7691610
    Abstract: The present invention provides a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis. The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The invention also provides methods for using the antibodies to detect the presence of the protein with antibodies and methods for using the polynucleotides to detect the presence of Zven RNA.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 6, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • Human Zven polypeptides
    Patent number: 7691585
    Abstract: The present invention provides polypeptides and compositions comprising amino acid residues 23 to 108 of SEQ ID NO: 2, polypeptides and compositions comprising amino acid residues 28 to 108 of SEQ ID NO: 2, including affinity tags and the like, useful for stimulating gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 6, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • ANTIBODIES TO MAMMALIAN CYTOKINE-LIKE FACTOR 7
    Publication number: 20100076179
    Abstract: Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.
    Type: Application
    Filed: September 16, 2009
    Publication date: March 25, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Teresa Gilbert